Autopsy report · NCT01713569

Feasibility Study: Histological Characterization After Treatment With the Ulthera® System

“Slow subject enrollment; study to be obtained is no longer required.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Ulthera, Inc

Sponsor type

Industry

Conditions

Skin Laxity

Interventions

Ulthera Treatment

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• T2 FSL2 Weight Loss
  “Slow enrollment and Study no longer required” (86% match in meaning)
• LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
  “Study was discontinued due to slow enrollment” (81% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (79% match in meaning)
• Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
  “Slow enrollment; study terminated.” (79% match in meaning)
• Study in Adult Subjects Undergoing Posterolateral Thoracotomy
  “Slow study enrollment” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.